Discussion| Volume 126, P151, April 2019

Author Reply

      We thank Dr. Gejerman for recognizing the importance of this work. Indeed, we agree that the results of the present study are hypothesis generating. Thus, we enthusiastically await the long-term results of RTOG0815 which, with a planned enrollment of 1520 men with intermediate-risk prostate cancer, randomized men to either dose-escalated RT alone vs dose-escalated RT combined with 6 months of androgen deprivation, stratified by the number of risk factors, ACE-27, Adult Comorbidity Evaluation 27 comorbidity status, and RT modality. These data will validate or refute the hypothesis-generating finding in the present study, which suggests that a higher prostate-specific antigen nadir and shorter time to prostate-specific antigen nadir are prognostic factors and potential surrogates for prostate cancer-specific mortality, in a population treated with dose-escalated RT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect